Engineering pyroptotic vesicles as personalized cancer vaccines

Area of Science:

• Biotechnology
• Immunology
• Oncology

Background:

• Current tumour vaccines face limitations due to individual variability, tumour complexity, and adverse effects.
• Personalized cancer vaccines are needed to overcome these challenges and improve therapeutic outcomes.
• Extracellular vesicles (EVs) are emerging as promising platforms for drug delivery and immunotherapy.

Purpose of the Study:

• To engineer pyroptotic vesicles (PVs) as a novel tumour vaccine platform.
• To evaluate the efficacy of PV-based vaccines in preventing post-surgical tumour recurrence and metastasis.
• To investigate the underlying immune mechanisms of PV-based cancer immunotherapy.

Main Methods:

• Pyroptotic vesicles were extracted from pyroptotic tumour cells.
• PVs were loaded into a biocompatible hydrogel for post-surgical implantation.
• The efficacy of PV-based vaccines was assessed in post-surgical mouse models of cancer.
• Immune responses, including dendritic cell and T cell activation, were analyzed.

Main Results:

• Pyroptotic vesicles demonstrated potent tumour antigen presentation and immune stimulation.
• PV-based vaccines significantly inhibited tumour recurrence and metastasis compared to exosome- and apoptotic body-based vaccines.
• The PV-based vaccine elicited robust antigen-specific dendritic cell and T cell responses against both model and neoantigens.
• The platform showed potential for tailoring immune responses for individual cancer patients.

Conclusions:

• Pyroptotic vesicles represent a promising and adaptable platform for developing personalized cancer vaccines.
• PV-based vaccines offer a strategy to overcome current limitations in cancer immunotherapy.
• This approach holds potential for preventing tumour recurrence and treating individual cancer patients effectively.